dihydroxyphenylalanine and Astrocytoma, Grade IV

dihydroxyphenylalanine has been researched along with Astrocytoma, Grade IV in 9 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Research

Studies (9)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Proportion of Grade IV MGMT Un-methylated Patients That Experience Confirmed-progression-free Survival at 6 Months (CPFS6)

"The proportion of Grade IV MGMT un-methylated patients that experience confirmed-progression-free survival at 6 months (CPFS6). Progression is defined by any of the following:~≥25% increase in the sum of products of perpendicular diameters of enhancing lesions compared to the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids~Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events~Any new lesion~Clear clinical deterioration not attributable to other causes apart from the tumor or changes in corticosteroid dose.~Failure to return for evaluation due to death or deteriorating condition~Clear progression of non-measurable disease" (NCT01991977)
Timeframe: Time from registration to the confirmed disease progression, assessed at 6 months

Trials

1 trial available for dihydroxyphenylalanine and Astrocytoma, Grade IV

Other Studies

8 other studies available for dihydroxyphenylalanine and Astrocytoma, Grade IV